Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life-Reference-Cited by-同舟云学术

Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life

Published:2021-02-11 Issue:2 Volume:4 Page:e2033004
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Arciero Vanessa¹,Delos Santos Seanthel¹,Koshy Liza¹,Rahmadian Amanda¹,Saluja Ronak¹,Everest Louis¹,Parmar Ambica²³,Chan Kelvin K. W.¹²³⁴

Affiliation:

1. Evaluative Clinical Sciences, Odette Cancer Centre Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada

2. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada

3. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

4. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2776170/arciero_2021_oi_201013_1612371652.39019.pdf

Reference36 articles.

1. Cancer patient preferences for quality and length of life.;Meropol;Cancer,2008

2. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines.;Salas-Vega;JAMA Oncol,2017

3. Surrogate end points in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?;Kemp;BMC Med,2017

4. Progression-free survival as an end-point in solid tumours—perspectives from clinical trials and clinical practice.;Robinson;Eur J Cancer,2014

5. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.;Sridhara;J Natl Cancer Inst,2010

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

2. Medical Statistics in Drug Development and Regulatory Approval;Advances in Bioinformatics and Biomedical Engineering;2024-07-18

3. A novel framework to assess haematology and oncology registration trials: The THEOREMM project;European Journal of Clinical Investigation;2024-06-27

4. Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005–2020: an observational study;The Lancet Regional Health - Western Pacific;2024-05

5. Clinical trials and tribulations;EMBO Reports;2024-02-05